Court Rules in Favor of Biovail in Tiazac Class Actions

Biovail Corporation announced today that a United States District Judge for the District of Columbia has granted Biovail's motions for summary judgment, thereby dismissing complaints in two related putative class-action cases asserting antitrust claims by purchasers of Biovail's Tiazac product. The complaints, launched in 2001 and 2003, alleged that Biovail's listing with the FDA of a patent for Tiazac improperly delayed the entry of a competing generic product. Plaintiffs further alleged that the delay in entry of a generic product into the market caused them to pay a premium to purchase Biovail's brand-name product.

Yahoo News (http://biz.yahoo.com/bw/050404/45447.html?.v=1)